CyberKnife Market by Application (Tumor, Cancer, Vascular Malformation, and Others), End Use (Hospitals, Outpatient facilities, and Research & Manufacturing), and Region (North America, Europe, Asia-Pacific, and LAMEA): Opportunity Analysis and Industry Forecast, 2023-2032

CyberKnife Overview

A robotic, non-invasive radiation therapy technology called CyberKnife is used to treat tumors and other diseases. Accuray Incorporated created it, and the FDA approved it in 1999. The CyberKnife device is made to give extremely precise radiation therapy to target specific body parts, especially tumours, while sparing nearby healthy tissues. A robotic arm fitted with a linear accelerator that fires highly focussed radiation beams from various angles makes up the CyberKnife system. The treatment region may be targeted precisely and dynamically thanks to the robotic arm. The CyberKnife is outfitted with cutting-edge imaging equipment, including cone-beam CT scans and X-rays, which provides real-time imaging while administering treatment. This makes it possible to continuously monitor the patient and modify the treatment plan to take into account any patient movement or shifts in the tumor's position.

Global CyberKnife Market Analysis

The global CyberKnife market size was $458.2 million in 2022 and is predicted to grow with a CAGR of 18.6%, by generating a revenue of $2,522.2 million by 2032.

COVID-19 Impact on Global CyberKnife Market

During the peak of the pandemic, several medical procedures, including some cancer treatments, were postponed or delayed in order to prioritise COVID-19 patients and lower the risk of virus transmission. This might have had an impact on how often CyberKnife treatments were used. Reduced patient volumes for non-urgent treatments resulted from some patients and healthcare professionals expressing worries about visiting medical facilities for treatment during the pandemic.

There may be an increase in demand for therapies that were postponed or delayed during the pandemic, particularly CyberKnife treatments, with the removal of pandemic-related restrictions and a focus on healthcare service normalisation. Patients and healthcare professionals may place a higher value on non-invasive procedures like CyberKnife since they prioritise solutions that lower the risk of infection and do not require invasive surgery.

Minimally Invasive Treatments to Drive the Market Growth

The demand for cutting-edge and potent cancer treatment options, such as CyberKnife, which provides precise and focused radiation therapy, has surged as a result of the rising incidence of cancer throughout the world. Patients and medical professionals are increasingly looking for less invasive therapy options that deliver faster healing, fewer side effects, and better quality of life. The non-intrusiveness of CyberKnife fits this need. The capabilities and treatment possibilities of the CyberKnife have been increased as a result of ongoing developments in imaging, treatment planning, and robotic accuracy. Patients and healthcare professionals are becoming more aware of cutting-edge therapy choices like CyberKnife, which has led to a rise in its use. CyberKnife is now used to treat tumours in the spine, lungs, liver, prostate, pancreatic, and other places in addition to brain tumours, which has increased its relevance and uptake in a variety of medical specialties.

Limited Availability to Restrain Market Growth

High-tech and sophisticated medical gadgets like CyberKnife systems can be pricey to buy and install. Some healthcare facilities may not be able to afford the initial capital expenditure and recurring maintenance expenditures. CyberKnife therapy facilities might not be widely available, especially in some areas or nations. This restricted access might make it difficult for patients to use this cutting-edge radiation therapy option. Despite being shorter than traditional radiation therapy sessions, CyberKnife treatments may still necessitate many sessions spread across several days. Some patients could like or need more expedited treatment plans. The use of cutting-edge technologies like CyberKnife may raise ethical questions, as with any medical procedure, especially when patients have severe medical conditions or few other therapeutic alternatives. Facilities providing CyberKnife treatments may face difficulties adhering to legal regulations and radiation safety norms.

 Growing Incidence of Cancer to Drive Excellent Opportunities

In the upcoming years, it is expected that there will be an increase in the incidence of cancer worldwide, fueling the demand for cutting-edge and efficient cancer treatment alternatives. The CyberKnife is a useful tool in the treatment of cancer due to its capacity to offer precise and targeted radiation therapy. A wider spectrum of medical diseases will be treated with CyberKnife technology as it continues to advance, thanks to its enhanced imaging capabilities, treatment planning algorithms, and robotic precision. The adoption of CyberKnife is anticipated to benefit from the trend towards personalised medicine and individualised treatment regimens since it enables highly customised radiation therapy to address the particular needs of each patient.

To know more about global cyberKnife market opportunities, get in touch with our analysts here.

Global CyberKnife Market Share, by Application, 2022

The cancer sub-segment accounted for the highest share in 2022. The focused treatment of malignant tumours is made possible by the CyberKnife's capacity to deliver extremely precise and accurate radiation beams while minimising harm to nearby healthy tissues. This accuracy is particularly important for tumours that are close to important organs or structures. Patients who might not be good candidates for surgery or conventional radiation treatments may find CyberKnife to be an appealing alternative due to its non-invasive method of administering radiation therapy. For some cancer types, it offers a minimally invasive alternative. Patients with multisite or multifocal cancers benefit from CyberKnife's capacity to simultaneously treat several tumours in various parts of the body.

Global CyberKnife Market Share, by End Use, 2022

The hospitals sector accounted for the highest market size in 2022. Hospitals work hard to provide patients with the most cutting-edge treatment alternatives. Precision and non-invasiveness of CyberKnife make it a desirable addition to a hospital's suite of cancer therapy tools. Multidisciplinary treatment strategies are frequently emphasised by hospitals that provide comprehensive cancer care. This strategy is in line with CyberKnife's adaptability in treating tumours in various regions of the body, which promotes cooperation across diverse medical specialisations. Hospitals work to enhance patient satisfaction and treatment outcomes. The accurate radiation therapy delivered by CyberKnife may improve tumour control and minimise adverse effects, which will improve treatment outcomes.

Global CyberKnife Market Share, by Region, 2022

North America CyberKnife market accounted for the highest market share in 2022. The incidence of cancer has significantly increased in North America over time, which has increased the demand for cutting-edge, precise cancer treatment solutions like CyberKnife. Due to the region's significant emphasis on research and development, CyberKnife systems have undergone continual technical developments that have improved their effectiveness, accuracy, and usability. The healthcare system in North America is well-established and includes many hospitals and cancer treatment facilities, making cutting-edge medical equipment like CyberKnife accessible. In order to promote the use of CyberKnife, favourable reimbursement procedures have been devised in both the U.S. and Canada for specific indications.

Competitive Scenario in the Global CyberKnife Market

Product development and geographic expansion are major strategies in the highly competitive global CyberKnife market. The CyberKnife S7 System, a cutting-edge tool that combines speed, advanced precision, and real-time artificial intelligence (AI)-driven motion tracking and synchronisation treatment delivery for all stereotactic radiosurgery (SRS) and stereotactic body radiation therapy (SBRT) treatment in less than 15 minutes, was introduced by Accuray Incorporated on June 26, 2020. The CyberKnife S7 System, a robotic, non-invasive radiation therapy system that can treat both malignant and benign tumours throughout the body as well as neurological diseases, is the next-generation CyberKnife platform.

Some of the leading cyberKnife market players are Accuray Incorporated, Varian Medical Systems, Koninklijke Philips, and Others.